BeOne Medicines (ONC) Short-term Investments (2015 - 2023)

BeOne Medicines (ONC) has reported Short-term Investments for 9 consecutive years, with $2.6 million the latest figure, recorded in Q4 2023.

• In Q4 2023, Short-term Investments fell 99.61% year-over-year to $2.6 million; the TTM figure through Dec 2023 stood at $2.6 million (down 99.61% YoY), while the FY2023 annual figure was $2.6 million, down 99.61% from the prior year.
• Short-term Investments slipped to $2.6 million in Q4 2023 per ONC's latest filing, from $107.0 million in the prior quarter.
• Across five years, Short-term Investments topped out at $3.3 billion in Q4 2020 and bottomed at $2.6 million in Q4 2023.
• Historically, Short-term Investments has averaged $1.4 billion across 5 years, with a median of $1.0 billion in 2022.
• Annual changes were most pronounced in 2020 — Short-term Investments soared 796.21% — and 2023, when it tumbled 99.61%.
• BeOne Medicines' Short-term Investments stood at $364.7 million in 2019, then jumped by 796.21% to $3.3 billion in 2020, then sank by 31.41% to $2.2 billion in 2021, then tumbled by 70.33% to $665.3 million in 2022, then sank by 99.61% to $2.6 million in 2023.
• Business Quant data shows ONC's Short-term Investments at $2.6 million in Q4 2023, $107.0 million in Q3 2023, and $105.7 million in Q2 2023.